🇺🇸 FDA
Pipeline program

PEGPH20

Halo-110-101

Phase 1 small_molecule terminated

Quick answer

PEGPH20 for Cholangiocarcinoma Non-resectable is a Phase 1 program (small_molecule) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
HALOZYME THERAPEUTICS, INC.
Indication
Cholangiocarcinoma Non-resectable
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials